Effectiveness of Recombinant Human Bone Morphogenetic Protein‐2 in Socket Preservation: A Randomized Controlled Clinical and Sequential Human Histological Trial (BMP‐2 TRIAL)
ABSTRACT Objectives The aim of this study was to evaluate the effectiveness of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) coated biphasic calcium phosphate (BCP) in socket preservation in comparison to BCP. Material and Methods Patients who underwent extraction of maxillary premolars w...
Saved in:
| Main Authors: | , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2025-06-01
|
| Series: | Clinical and Experimental Dental Research |
| Subjects: | |
| Online Access: | https://doi.org/10.1002/cre2.70134 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| Summary: | ABSTRACT Objectives The aim of this study was to evaluate the effectiveness of recombinant human bone morphogenetic protein‐2 (rhBMP‐2) coated biphasic calcium phosphate (BCP) in socket preservation in comparison to BCP. Material and Methods Patients who underwent extraction of maxillary premolars were randomized to receive rhBMP‐2/BCP (n = 15) and BCP alone (n = 15). All sites were primarily closed using a pedicled connective tissue flap. Biopsy was carried out in patients at 3 (n = 10), 6 (n = 10), and 9 (n = 10) months. Results At 3 months, BMP and non‐BMP groups had 3.17% and 3.12% new bone formation, respectively, and 3.8% and 37.85% of residual grafts, respectively, and 25.86% and 25.99% connective tissue component, respectively. At 6 months, both groups revealed 67.42% and 16.55% essential bone growth, 1.74% and 3.04% of residual graft, and 1.3% and 67% connective tissue component, respectively. At 9 months, the BMP group revealed 93.6% new bone formation, 0.68% residual graft, and 1.9% connective tissue component, while the non‐BMP groups had 23.35% new bone formation, 4.45% residual graft, and 44.06% connective tissue component. Conclusion This study demonstrated that rhBMP‐2 coated BCP significantly enhanced early graft substitution in socket preservation sites compared to BCP alone. There was a significantly higher percentage of new bone formation in the rhBMP‐2/BCP group both at 6 and 9 months. Additionally, the rhBMP‐2/BCP group exhibited faster resorption of the graft material and earlier maturation of newly formed bone. These findings strongly suggest that rhBMP‐2/BCP can be an effective treatment modality for socket preservation, promoting predictable and accelerated bone regeneration. |
|---|---|
| ISSN: | 2057-4347 |